

December 30, 2024

## PRIOR AUTHORIZATION UPDATES FOR MARKETPLACE AND DSNP – EFFECTIVE MAR. 1, 2025

### SUMMARY OF NOTIFICATION

On March 1, 2025, Saphnelo (anifrolumab-fnia) and Vabysmo (faricimab-svoa) will be subject to Community Health Choice Medical Review Guideline policies with diagnostic and step therapy criteria. This will impact Marketplace and DSNP plans.

### KEY DETAILS

- Vabysmo (faricimab-svoa) J2777 will require a step through intravitreal Avastin in addition to clinical criteria.
- Saphnelo (anifrolumab-fnia) J0491 will require a step through Benlysta in addition to clinical criteria.

Please refer to our [Community provider website](#) under “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” for complete, updated Medical Review Guidelines (MRGs).